The multidistrict litigation established last year for all federally-filed Invokana lawsuits continues to grow, with dozens of new cases added to the proceeding in just the past month alone.
According to an October 12th Case Management Order, 865 cases are now pending in the U.S. District Court, District of New Jersey, all of which were filed on behalf of individuals who allegedly suffered diabetic ketoacidosis or other side effects due to their use of Invokana or Invokamet
The figure represents an increase of 90 filings since September 7th, when the Court reported 775 pending lawsuits.
The federal Invokana litigation is scheduled to convene its next Case Management Conference on November 16th at 11:00 a.m. Lead counsel and liaison counsel ate to appear at 10:00 a.m.
The Order further directs Counsel to submit via email a joint agenda 5 days prior to the conference, including an up-to-date list of Invokana lawsuits pending in the District of New Jersey. If there are any disagreements as to the agenda, counsel are to set forth each party’s position.
Invokana (canagliflozin) was approved by the U.S. Food & Drug Administration (FDA) in March 2013 and was the first SGLT2 inhibitor cleared by the agency to treat Type 2 diabetes. The FDA approved Invokamet (canagliflozin and metformin) the following year.
Invokana and other SGLT2 inhibitors lower blood sugar levels by inhibiting the absorption of glucose by the kidney, resulting its elimination via urine. While the drugs have proven effective, the FDA has recently issued a number of safety alerts regarding serious side effects potentially associated with their use.
In December 2015, the FDA announced that the labels for Invokana and other SGLT2 inhibitor drugs would be updated to include information about diabetic ketoacidosis, a dangerous condition that occurs when toxic acids called ketones accumulate in the blood. If not recognized and treated quickly, diabetic ketoacidosis can progress to diabetic coma and may even prove fatal.
The labels for Invokana, Invokamet and several other SGLT2 inhibitors were updated yet again in June 2016, after the medications were linked to more than 100 reports of acute kidney injury.
In May of this year, a new Black Box Warning – the strongest possible safety alert – was added to, the prescribing information for Invokana and Invokamet after canagliflozin was linked to an increased risk of leg and foot amputations.